Join the club for FREE to access the whole archive and other member benefits.

Ronjon Nag

Managing Director and Founder at R42 Group.

Dr. Ronjon Nag is an inventor, entrepreneur and a Stanford Distinguished Careers Institute Interdisciplinary Fellow based at the Stanford Center for Language and Information (CSLI). He is a founder and advisor/board member of multiple start-ups. His companies have been sold to Apple, BlackBerry, and Motorola. He has been awarded the Mountbatten Medal in the Royal Institution by the Institution of Engineering and Technology, and has been winner (Bounce Imaging-Board) of the $1m Verizon Powerful Answers Award.He has been a pioneer of smartphones and the 'app stores' they depend on. He has worked on neural networks, touch screens, mobile search, voice recognition, text prediction and handwriting recognition.

He has a Ph.D from Cambridge, an M.S from M.I.T and a B.Sc. from Birmingham in the UK.

Visit website: https://www.r42group.com/dr-ronjon-nag

 ronjonnag

 RonjonNag

See also: Company R42 Group - Company Inventing and Investing in AI, Science and Biotech.

Details last updated 09-Apr-2020

Ronjon Nag is also referenced in the following:

Global Healthspan Summit 2023

29-Nov-2023 to 30-Nov-2023

Longevity summit organised by Hevolution Foundation (Riyadh,Saudi Arabia)

Longevity Leaders World Congress 2021

04-May-2021 to 07-May-2021

The virtual event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX).

Longevity Leaders World Congress 2022

26-Feb-2022 to 27-Feb-2022

Event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX)

The Longevity Summit 2024

03-Dec-2024 to 04-Dec-2024

Longevity researchers, investors, and entrepreneurs speaking about eliminating disease of ageing by Longevity Global (Novato, CA, USA)

Ronjon Nag News

Mitrix gains funding to transfuse young mitochondria

Mitrix gains funding to transfuse young mitochondria

Longevity Technology - 28-Jan-2021

Trials on mitochondrial transfusion might help tackle many ageing diseases

R42 group launched $14 million funds aiming to extend longevity

R42 group launched $14 million funds aiming to extend longevity

Longevity Technology - 06-Jan-2021

Funding targets early-stage companies and postdoc researchers with unique ideas